4-(3-hydroxy-4-methylanilino)-6,7-dimethoxycinnoline | 197359-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(3-hydroxy-4-methylanilino)-6,7-dimethoxycinnoline
• 英文别名: 5-[(6,7-Dimethoxycinnolin-4-yl)amino]-2-methylphenol
• CAS: 197359-04-9
• 化学式: C₁₇H₁₇N₃O₃
• 分子量: 311.34
• InChiKey: SAWAMXLBPOIUQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  76.5
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS<br/>[FR] DERIVES DE 4, 6-DIALKOXY-CINNOLINE SUBSTITUES EN POSITION 4 EN TANT QU'INHIBITEURS DE PHOSPODIESTERASE 10 POUR LE TRAITEMENT DE SYNDROMES PSYCHIATRIQUES OU NEUROLOGIQUES
  申请人：MEMORY PHARM CORP

  公开号：WO2006028957A1

  公开（公告）日：2006-03-16

  The present disclosure relates generally to the field of phosphodiesterase 10 (PDE10) enzyme inhibition by cinnoline compounds of Formulas: (I) and (II); wherein R'-R3 and R15-R18 are as defined herein. Still further, the present invention provides methods for synthesizing compounds with such activity and selectivity, as well as methods of and corresponding pharmaceutical compositions for treating a patient, e.g., mammals, including humans, in need of PDE inhibition. Treatment is preferably for a disease state that involves elevated intracellular PDE10 levels or decreased cAMP and/or cGMP levels, e.g., involving neurological or psychiatric syndromes, especially those states associated with psychoses, most especially schizophrenia or bipolar disorder, obsessive-compulsive disorder, and/or Parkinson’s disease. In particular, such psychoses, obsessive-compulsive disorder, and/or Parkinson’s disease are due at least in part to catabolism of intracellular cAMP and/or cGMP levels by PDE10 enzymes or where such an impaired condition can be improved by increasing cAMP and/or cGMP levels.

  本公开涉及磷酸二酯酶10（PDE10）酶被Formula（I）和（II）的喹啉类化合物抑制；其中R'-R3和R15-R18如本文所定义。此外，本发明提供了合成具有此类活性和选择性的化合物的方法，以及用于治疗需要PDE抑制的患者，例如哺乳动物，包括人类的方法和相应的药物组合物。治疗最好用于涉及细胞内PDE10水平升高或cAMP和/或cGMP水平降低的疾病状态，例如涉及神经系统或精神症候群，尤其是与精神病、强迫症、帕金森病有关的状态。特别是这些精神病、强迫症和/或帕金森病至少部分是由PDE10酶分解细胞内cAMP和/或cGMP水平引起的，或者这种受损状态可以通过增加cAMP和/或cGMP水平来改善。
• Cinnoline derivatives and use as medicine
  申请人：ZENECA LIMITED

  公开号：US20030199513A1

  公开（公告）日：2003-10-23

  The invention relates to the use of cinnoline derivatives of formula (I) 1 wherein Z represents —O—, —NH—, —S— or —CH 2 —; m is an integer from 1 to 5; R 1 represents hydrogen, hydroxy, halogeno, nitro, cyano, trifluoromethyl, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylthio or NR 6 R 7 (wherein R 6 and R 7 , which may be the same or different, each represents hydrogen or C 1-3 alkyl); R 2 represents hydrogen, hydroxy, fluoro, chloro, methoxy, amino or nitro; R 3 represents hydroxy, halogeno, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkanoyloxy, trifluoromethyl, cyano, amino or nitro; R 4 represents hydrogen, hydroxy, halogeno, cyano, nitro, amino, trifluoromethyl, C 1-3 alkyl or a group R 5 —X 1 (wherein X 1 represents —O—, —CH 2 —, —S—, —SO—, —SO 2 —, —NR 8 CO—, —CONR 9 −, —SO 2 NR 10 —, —NR 11 SO 2 — or —NR 12 — (wherein R 8 , R 9 , R 10 , R 11 and R 12 each independently represents hydrogen, C 1-3 alkyl or C 1-3 alkoxy C 2-3 alkyl) and R 5 is an optionally substituted alkyl, carbocylic or heterocylic group which may be saturated or unsaturated and may be directly linked to the cinnoline ring or be linked via a carbon chain which may have heteroatom linking groups within it and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human being, processes for the preparation of such derivatives, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula (I). The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  本发明涉及使用式（I）的茜草啉衍生物，其中Z代表—O—，—NH—，—S—或—CH2—；m为1至5的整数；R1代表氢，羟基，卤素，硝基，氰基，三氟甲基，C1-3烷基，C1-3烷氧基，C1-3烷硫基或NR6R7（其中R6和R7，可以相同也可以不同，分别代表氢或C1-3烷基）；R2代表氢，羟基，氟，氯，甲氧基，氨基或硝基；R3代表羟基，卤素，C1-3烷基，C1-3烷氧基，C1-3烷酰氧基，三氟甲基，氰基，氨基或硝基；R4代表氢，羟基，卤素，氰基，硝基，氨基，三氟甲基，C1-3烷基或R5-X1基团（其中X1代表—O—，— —，—S—，—SO—，—SO2—，—NR8CO—，—CONR9−，—SO2NR10—，—NR11SO2—或—NR12—（其中R8，R9，R10，R11和R12各自独立地代表氢，C1-3烷基或C1-3烷氧基C2-3烷基），而R5是一个可选择的取代基的烷基，环烷基或杂环烷基，可以是饱和或不饱和的，并且可以直接连接到茜草啉环或通过一个碳链连接，该碳链可以在其中具有异原子连接基团，并且其盐，在制备用于在温血动物，如人类中产生抗血管生成和/或血管通透性降低作用的药物方面使用，制备这种衍生物的方法，包含式（I）化合物或其药学上可接受的盐作为活性成分的制药组合物和式（I）化合物。式（I）化合物及其药学上可接受的盐抑制VEGF的效应，在治疗包括癌症和类风湿性关节炎在内的多种疾病状态方面具有价值。
• Phosphodiesterase 10 inhibitors
  申请人：Arrington Phillip Mark

  公开号：US20060160814A1

  公开（公告）日：2006-07-20

  The present disclosure relates generally to the field of phosphodiesterase 10 (PDE10) enzyme inhibition by cinnoline compounds of Formulas I and II: wherein R 1 —R 3 and R 15 —R 18 are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本公开涉及使用公式I和II的茚啶类化合物抑制磷酸二酯酶10（PDE10）酶的领域：其中R1-R3和R15-R18如本文所定义。本公开还涉及制备这种化合物的方法，含有这种化合物的组合物以及使用它们的方法。
• CINNOLINE DERIVATIVES AND USE AS MEDICINE
  申请人：ZENECA LIMITED

  公开号：EP0888310A1

  公开（公告）日：1999-01-07
• 4-SUBSTITUTED 4,6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS
  申请人：Memory Pharmaceuticals Corporation

  公开号：EP1802585A1

  公开（公告）日：2007-07-04